Generics and biosimilars offer effective treatment alternatives to branded reference drugs at a lower cost. Despite their widespread use, patients have mis conceptions regarding their efficacy and safety. Layperson materials offer an important means by which patients can be educated in this regard. Here, we provide an overview of generics and biosimilars, describe how layperson materials fit into this landscape from a patientcentricity and regulatory perspective, and provide example language that can be used when developing layperson-orientated materials for generics and biosimilars.
Editor-in-Chief:
Co-Editor:
Managing Editor
Associate Editors:
Section Editors:
Ad-hoc Editors:
Editor Emeritus: